Paola Dongiovanni

List of Publications by Citations

151 papers	7,976 citations	50 h-index	85 g-index
183 ext. papers	9,767 ext. citations	5.7 avg, IF	5.93 L-index

#	Paper	IF	Citations
151	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. *Hepatology*, **2010**, 51, 1209-17	11.2	445
150	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. *Gastroenterology*, **2016**, 150, 1219-1230.e6	13.3	347
149	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. *Hepatology*, **2015**, 61, 506-14	11.2	311
148	Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. *Gastroenterology*, **2002**, 122, 274-80	13.3	253
147	Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. *American Journal of Gastroenterology*, **2007**, 102, 1251-8	0.7	234
146	PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. *Human Molecular Genetics*, **2014**, 23, 4077-85	5.6	230
145	Statin use and non-alcoholic steatohepatitis in at risk individuals. *Journal of Hepatology*, **2015**, 63, 705-12	13.4	227
144	Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. *Journal of Hepatology*, **2011**, 55, 920-32	13.4	205
143	HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. *Gastroenterology*, **2010**, 138, 905-12	13.3	203
142	I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. *Hepatology*, **2010**, 52, 1274-80	11.2	200
141	Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. *Hepatology*, **2011**, 53, 791-9	11.2	199
140	PNPLA3 I148M polymorphism and progressive liver disease. *World Journal of Gastroenterology*, **2013**, 19, 6969-78	5.6	153
139	Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. *Current Pharmaceutical Design*, **2013**, 19, 5219-38	3.3	148
138	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. *Journal of Internal Medicine*, **2018**, 283, 356-370	10.8	140
137	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. *Scientific Reports*, **2017**, 7, 4492	4.9	131
136	Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. *Diabetes*, **2008**, 57, 1355-62	0.9	128
135	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. *Journal of Hepatology*, **2012**, 56, 448-54	13.4	126

134	Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. *American Journal of Pathology*, **2008**, 172, 738-47	5.8	124
133	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. *Gut*, **2010**, 59, 267-73	19.2	117
132	Dietary iron overload induces visceral adipose tissue insulin resistance. *American Journal of Pathology*, **2013**, 182, 2254-63	5.8	101
131	Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. *World Journal of Gastroenterology*, **2014**, 20, 12945-55	5.6	98
130	Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. *BioMed Research International*, **2015**, 2015, 460190	3	89
129	Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. *Science Translational Medicine*, **2018**, 10,	17.5	85
128	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1604-1611.e1	6.9	83
127	Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. *Blood*, **2001**, 97, 3707-12	2.2	80
126	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. *Journal of Hepatology*, **2016**, 64, 682-90	13.4	79
125	Liver fat accumulation is associated with circulating PCSK9. *Annals of Medicine*, **2016**, 48, 384-91	1.5	78
124	Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. *Hepatology*, **2006**, 44, 857-64	11.2	74
123	Nutritional therapy for nonalcoholic fatty liver disease. *Journal of Nutritional Biochemistry*, **2016**, 29, 1-11	6.3	72
122	PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. *Human Molecular Genetics*, **2016**, 25, 5212-5222	5.6	71
121	The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. *Hepatology*, **2016**, 63, 787-98	11.2	70
120	miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	70
119	Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. *Cell Metabolism*, **2020**, 31, 406-421.e7	24.6	69
118	Genetics of nonalcoholic fatty liver disease. *Metabolism: Clinical and Experimental*, **2016**, 65, 1026-37	12.7	67
117	Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 683-90	9.4	67

116	Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. *Digestive and Liver Disease*, **2003**, 35, 172-8	3.3	66
115	A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. *World Journal of Gastroenterology*, **2014**, 20, 3002-10	5.6	66
114	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. *Journal of Hepatology*, **2011**, 55, 1409-14	13.4	65
113	The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. *Journal of Medical Genetics*, **2004**, 41, 946-50	5.8	65
112	Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. *Nutrition, Metabolism and Cardiovascular Diseases*, **2011**, 21, 568-75	4.5	62
111	Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. *Haematologica*, **2007**, 92, 1037-42	6.6	60
110	Iron and insulin resistance. *Alimentary Pharmacology and Therapeutics*, **2005**, 22 Suppl 2, 61-3	6.1	60
109	Alcohol or Gut Microbiota: Who Is the Guilty?. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	59
108	PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity. *Journal of Nutrition*, **2015**, 145, 1687-91	4.1	59
107	Interferon lambda 4 rs368234815 TT>□ variant is associated with liver damage in patients with nonalcoholic fatty liver disease. *Hepatology*, **2017**, 66, 1885-1893	11.2	59
106	Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. *Hepatology*, **2013**, 58, 1245-52	11.2	56
105	Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. *American Journal of Pathology*, **2010**, 176, 1006-17	5.8	54
104	TNF alpha polymorphisms, HFE gene mutations and acquired factors in Italian patients with porphyria cutanea tarda. *Journal of Hepatology*, **2002**, 36, 157-158	13.4	53
103	Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. *Journal of Hepatology*, **2010**, 53, 927-33	13.4	51
102	The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. *BMC Gastroenterology*, **2012**, 12, 111	3	50
101	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. *Journal of Hepatology*, **2021**, 74, 775-782	13.4	50
100	Relationship between TNF-alpha and iron metabolism in differentiating human monocytic THP-1 cells. *British Journal of Haematology*, **2000**, 110, 978-84	4.5	47
99	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. *Hepatology*, **2015**, 62, 111-7	11.2	46

98	LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2012**, 54, 588-93	2.8	46
97	Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. *BMC Gastroenterology*, **2010**, 10, 102	3	46
96	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. *PLoS ONE*, **2016**, 11, e0163069	3.7	45
95	The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. *Scientific Reports*, **2019**, 9, 11585	4.9	44
94	Genetic and Epigenetic Modifiers of Alcoholic Liver Disease. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	44
93	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. *Scientific Reports*, **2019**, 9, 3682	4.9	42
92	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2310-2319.e6	6.9	42
91	The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. *Nutrients*, **2019**, 11,	6.7	42
90	PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease. *Digestive and Liver Disease*, **2013**, 45, 619-24	3.3	42
89	Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. *World Journal of Gastroenterology*, **2012**, 18, 2813-20	5.6	42
88	A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	39
87	Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. *Clinical Science*, **2017**, 131, 1301-1315	6.5	38
86	Hepatic iron is the major determinant of serum ferritin in NAFLD patients. *Liver International*, **2018**, 38, 164-173	7.9	38
85	Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. *Liver International*, **2019**, 39, 1742-1754	7.9	37
84	The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. *PLoS ONE*, **2012**, 7, e48804	3.7	37
83	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. *EBioMedicine*, **2020**, 52, 102658	8.8	36
82	PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma. *PLoS ONE*, **2013**, 8, e75982	3.7	36
81	The UCP2 -866□G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. *Liver International*, **2015**, 35, 1574-80	7.9	35

80	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. *PLoS ONE*, **2016**, 11, e0162473	3.7	34
79	Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. *Gut*, **2020**, 69, 1855-1866	19.2	34
78	Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. *International Journal of Obesity*, **2013**, 37, 986-92	5.5	33
77	A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis. *Hormone and Metabolic Research*, **2010**, 42, 854-9	3.1	33
76	The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target?. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 229-42	4.2	32
75	Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. *Alimentary Pharmacology and Therapeutics*, **2012**, 35, 1434-42	6.1	32
74	TNFalpha genotype affects TNFalpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. *Journal of Hepatology*, **2005**, 43, 944-50	13.4	32
73	Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. *World Journal of Gastroenterology*, **2012**, 18, 3782-6	5.6	31
72	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2660-2669	5.6	30
71	High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload. *PLoS ONE*, **2015**, 10, e0116855	3.7	30
70	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. *Hepatology Communications*, **2018**, 2, 666-675	6	30
69	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. *Cancer Medicine*, **2017**, 6, 1930-1940	4.8	29
68	gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. *Journal of Lipid Research*, **2019**, 60, 1144-1153	6.3	27
67	Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. *Journal of Hepatology*, **2012**, 57, 1319-25	13.4	27
66	Klotho gene variation is associated with liver damage in children with NAFLD. *Journal of Hepatology*, **2020**, 72, 411-419	13.4	27
65	Nutrition and Genetics in NAFLD: The Perfect Binomium. *International Journal of Molecular Sciences* , **2020**, 21,	6.3	26
64	HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 1331-7	6.9	24
63	Hepcidin resistance in dysmetabolic iron overload. *Liver International*, **2016**, 36, 1540-8	7.9	22

62	A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. *Journal of Viral Hepatitis*, **2011**, 18, 628-30	3.4	22
61	Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance. *European Journal of Clinical Investigation*, **2014**, 44, 627-33	4.6	21
60	Iron Stores, Hepcidin, and Aortic Stiffness in Individuals with Hypertension. *PLoS ONE*, **2015**, 10, e0134635	3.7	21
59	mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. *Nutrients*, **2019**, 11,	6.7	19
58	HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients. *American Journal of Nephrology*, **2007**, 27, 101-7	4.6	19
57	Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?. *Metabolism: Clinical and Experimental*, **2021**, 117, 154708	12.7	19
56	The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. *BMC Nephrology*, **2013**, 14, 48	2.7	17
55	Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility?. *PPAR Research*, **2013**, 2013, 452061	4.3	17
54	MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. *EBioMedicine*, **2020**, 57, 102866	8.8	17
53	Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. *Gastroenterology*, **2017**, 153, 1568-1580.e10	13.3	13
52	Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. *European Journal of Clinical Investigation*, **2021**, 51, e13519	4.6	13
51	Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2019**, 1864, 158523	5	12
50	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9: The Role of STAT3. *American Journal of Pathology*, **2020**, 190, 2226-2236	5.8	12
49	Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. *Journal of Hepatology*, **2013**, 58, 399-401	13.4	11
48	HFE genotype influences erythropoiesis support requirement in hemodialysis patients: a prospective study. *American Journal of Nephrology*, **2008**, 28, 311-6	4.6	11
47	HFE mutations in nonalcoholic fatty liver disease. *Hepatology*, **2008**, 47, 1794-5; author reply 1795-6	11.2	11
46	What is the contribution of differences in three measures of tumor necrosis factor-alpha activity to insulin resistance in healthy volunteers?. *Metabolism: Clinical and Experimental*, **2003**, 52, 1593-6	12.7	10
45	PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. *Liver International*, **2021**, 41, 321-332	7.9	10

44	Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C. *PLoS ONE*, **2014**, 9, e106022	3.7	9
43	Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis. *Science Translational Medicine*, **2021**, 13,	17.5	9
42	FGF23 and Fetuin-A Interaction in the Liver and in the Circulation. *International Journal of Biological Sciences*, **2018**, 14, 586-598	11.2	9
41	Iron overload induces hypogonadism in male mice via extrahypothalamic mechanisms. *Molecular and Cellular Endocrinology*, **2017**, 454, 135-145	4.4	8
40	Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations: response to Equitani et al. *Diabetes Care*, **2008**, 31, e18; author reply e19	14.6	8
39	TNFalpha promoter polymorphisms. *Methods in Molecular Medicine*, **2004**, 98, 47-58		8
38	Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	8
37	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 517-519	6.9	8
36	Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. *Journal of Hepatology*, **2021**, 75, 506-513	13.4	8
35	CDKN1A: a double-edged sword in fatty liver?. *Cell Cycle*, **2014**, 13, 1371-2	4.7	7
34	Dysmetabolic Hyperferritinemia and Dysmetabolic Iron Overload Syndrome (DIOS): Two Related Conditions or Different Entities?. *Current Pharmaceutical Design*, **2020**, 26, 1025-1035	3.3	7
33	A novel alpha1-antitrypsin null variant (PiQ0Milano). *World Journal of Hepatology*, **2013**, 5, 458-61	3.4	7
32	Genetics Is of the Essence to Face NAFLD. *Biomedicines*, **2021**, 9,	4.8	7
31	Reply: To PMID 25251399. *Hepatology*, **2015**, 62, 660	11.2	6
30	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. *Cellular and Molecular Gastroenterology and Hepatology*, **2021**,	7.9	6
29	The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. *Cancers*, **2021**, 13,	6.6	6
28	Particulate matter phagocytosis induces tissue factor in differentiating macrophages. *Journal of Applied Toxicology*, **2016**, 36, 151-60	4.1	6
27	Increased circulating adiponectin in males with chronic HCV hepatitis. *European Journal of Internal Medicine*, **2015**, 26, 635-9	3.9	5

26	From Environment to Genome and Back: A Lesson from Mutations. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	5
25	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. *Annals of Hepatology*, **2014**, 13, 568-571	3.1	4
24	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2020**, 1865, 158765	5	4
23	GNPAT p.D519G variant and iron metabolism during oral iron tolerance test. *Hepatology*, **2017**, 65, 384-385	11.2	3
22	Can nonalcoholic steatohepatitis trigger porphyria cutanea tarda clinical manifestations?. *Internal and Emergency Medicine*, **2009**, 4, 91-2	3.7	3
21	Ferroportin-1 in the recurrence of hepatic iron overload after liver transplantation. *Digestive and Liver Disease*, **2009**, 41, e17-20	3.3	3
20	Iron genes, dysmetabolism and fibrosis in chronic hepatitis C. *Journal of Hepatology*, **2008**, 48, 513-4; author reply 514-5	13.4	3
19	Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. *Exploration of Medicine*, **2020**, 1, 218-243	1.1	3
18	MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients. *Journal of Internal Medicine*, **2021**,	10.8	3
17	Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Hepatology Communications*, **2021**,	6	3
16	Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver. *Nature Communications*, **2021**, 12, 1822	17.4	3
15	Rare ceruloplasmin variants are associated with hyperferritinemia and increased hepatic iron in NAFLD patients: results from a NGS study. *Journal of Hepatology*, **2018**, 68, S58-S59	13.4	3
14	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. *Liver International*, **2021**, 41, 2712-2719	7.9	3
13	MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver. *Digestive and Liver Disease*, **2016**, 48, e7-e8	3.3	2
12	T-ARMS-PCR for the evaluation of rs12979860 IL28B genotype: an optimized protocol. *Journal of Viral Hepatitis*, **2012**, 19, 228-228	3.4	2
11	IL28B rs12979860 polymorphism influences serum TNFalpha levels in chronic hepatitis C. *Digestive and Liver Disease*, **2013**, 45, 348-9	3.3	2
10	Serum hyaluronic acid for the screening of progressive nonalcoholic steatohepatitis in children: a promising approach. *Translational Research*, **2010**, 156, 226-8	11	2
9	Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 830-843	6.1	2

8	Impact of natural neuromedin-B receptor variants on iron metabolism. *American Journal of Hematology*, **2020**, 95, 167-177	7.1	2
7	Genetic variants in the MTHFR are not associated with fatty liver disease. *Liver International*, **2020**, 40, 1934-1940	7.9	1
6	TNFalpha promoter polymorphisms in Italian patients with porphyria cutanea tarda. *Digestive and Liver Disease*, **2003**, 35, 596-7	3.3	1
5	PSD3 downregulation confers protection against fatty liver disease.. *Nature Metabolism*, **2022**, 4, 60-75	14.6	1
4	Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies.. *Biomedicines*, **2022**, 10,	4.8	1
3	The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. *EBioMedicine*, **2021**, 65, 103249	8.8	1
2	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. *Annals of Hepatology*, **2014**, 13, 568-71	3.1	1
1	Reply to "Statin treatment for non-alcoholic steatohepatitis". *Journal of Hepatology*, **2016**, 64, 242-3	13.4	